tetano
Editor, Senior Moderator
World J Gastroenterol
. 2023 Apr 14;29(14):2064-2077.
doi: 10.3748/wjg.v29.i14.2064. Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies
Naina Khullar[SUP] 1 [/SUP], Jasvinder Singh Bhatti[SUP] 2 [/SUP], Satwinder Singh[SUP] 3 [/SUP], Bhawana Thukral[SUP] 4 [/SUP], P Hemachandra Reddy[SUP] 5 [/SUP], Gurjit Kaur Bhatti[SUP] 6 [/SUP]
Affiliations
As of June 2022, more than 530 million people worldwide have become ill with coronavirus disease 2019 (COVID-19). Although COVID-19 is most commonly associated with respiratory distress (severe acute respiratory syndrome), meta-analysis have indicated that liver dysfunction also occurs in patients with severe symptoms. Current studies revealed distinctive patterning in the receptors on the hepatic cells that helps in viral invasion through the expression of angiotensin-converting enzyme receptors. It has also been reported that in some patients with COVID-19, therapeutic strategies, including repurposed drugs (mitifovir, lopinavir/ritonavir, tocilizumab, etc.) triggered liver injury and cholestatic toxicity. Several proven indicators support cytokine storm-induced hepatic damage. Because there are 1.5 billion patients with chronic liver disease worldwide, it becomes imperative to critically evaluate the molecular mechanisms concerning hepatotropism of COVID-19 and identify new potential therapeutics. This review also designated a comprehensive outlook of comorbidities and the impact of lifestyle and genetics in managing patients with COVID-19.
Keywords: COVID-19; Cytokine storm; Liver damage; Molecular mechanisms; Pharmacotherapy.
. 2023 Apr 14;29(14):2064-2077.
doi: 10.3748/wjg.v29.i14.2064. Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies
Naina Khullar[SUP] 1 [/SUP], Jasvinder Singh Bhatti[SUP] 2 [/SUP], Satwinder Singh[SUP] 3 [/SUP], Bhawana Thukral[SUP] 4 [/SUP], P Hemachandra Reddy[SUP] 5 [/SUP], Gurjit Kaur Bhatti[SUP] 6 [/SUP]
Affiliations
- PMID: 37122601
- PMCID: PMC10130970
- DOI: 10.3748/wjg.v29.i14.2064
As of June 2022, more than 530 million people worldwide have become ill with coronavirus disease 2019 (COVID-19). Although COVID-19 is most commonly associated with respiratory distress (severe acute respiratory syndrome), meta-analysis have indicated that liver dysfunction also occurs in patients with severe symptoms. Current studies revealed distinctive patterning in the receptors on the hepatic cells that helps in viral invasion through the expression of angiotensin-converting enzyme receptors. It has also been reported that in some patients with COVID-19, therapeutic strategies, including repurposed drugs (mitifovir, lopinavir/ritonavir, tocilizumab, etc.) triggered liver injury and cholestatic toxicity. Several proven indicators support cytokine storm-induced hepatic damage. Because there are 1.5 billion patients with chronic liver disease worldwide, it becomes imperative to critically evaluate the molecular mechanisms concerning hepatotropism of COVID-19 and identify new potential therapeutics. This review also designated a comprehensive outlook of comorbidities and the impact of lifestyle and genetics in managing patients with COVID-19.
Keywords: COVID-19; Cytokine storm; Liver damage; Molecular mechanisms; Pharmacotherapy.